Cargando…
A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()()
AIM: SMAD4 immunohistochemistry is considered a valuable prognostic marker in colorectal cancer, but individual studies have often been small and the results variable. A meta-analysis could potentially clarify these findings. METHODS: In September 2014, a Pubmed and Google Scholar search was conduct...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350636/ https://www.ncbi.nlm.nih.gov/pubmed/25749173 http://dx.doi.org/10.1016/j.tranon.2014.11.003 |
_version_ | 1782360213089681408 |
---|---|
author | Voorneveld, Philip W. Jacobs, Rutger J. Kodach, Liudmila L. Hardwick, James C.H. |
author_facet | Voorneveld, Philip W. Jacobs, Rutger J. Kodach, Liudmila L. Hardwick, James C.H. |
author_sort | Voorneveld, Philip W. |
collection | PubMed |
description | AIM: SMAD4 immunohistochemistry is considered a valuable prognostic marker in colorectal cancer, but individual studies have often been small and the results variable. A meta-analysis could potentially clarify these findings. METHODS: In September 2014, a Pubmed and Google Scholar search was conducted to find publications that reported the prognostic value of SMAD4 expression. A meta-analysis was performed to clarify the association between SMAD4 expression and survival outcomes. RESULTS: 137 studies were found, of which 13 were considered eligible. The studies consisted of a total of 3800 patients. Three different endpoints were taken into account, namely, overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). In addition, the studies were divided into univariate and multivariate analyses. The pooled hazard ratios were given as follows: univariate CSS = 1.75 [95% confidence interval (CI): 0.93-3.32; z= 1.69; P= .09]; multivariate CSS = 2.17 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate DFS = 2.11 (95% CI: 1.36-3.28; z= 3.32; P= .001); multivariate DFS = 2.15 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate OS and DFS = 2.30 (95% CI: 1.41-3.73; z= 3.36; P= .001); univariate OS = 2.28 (95% CI: 1.30-4.00; z= 2.89; P= .004). CONCLUSION: The results of the presented meta-analyses indicate that SMAD4 expression status using immunohistochemistry is a prognostic marker for patient survival. |
format | Online Article Text |
id | pubmed-4350636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43506362015-03-09 A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() Voorneveld, Philip W. Jacobs, Rutger J. Kodach, Liudmila L. Hardwick, James C.H. Transl Oncol Article AIM: SMAD4 immunohistochemistry is considered a valuable prognostic marker in colorectal cancer, but individual studies have often been small and the results variable. A meta-analysis could potentially clarify these findings. METHODS: In September 2014, a Pubmed and Google Scholar search was conducted to find publications that reported the prognostic value of SMAD4 expression. A meta-analysis was performed to clarify the association between SMAD4 expression and survival outcomes. RESULTS: 137 studies were found, of which 13 were considered eligible. The studies consisted of a total of 3800 patients. Three different endpoints were taken into account, namely, overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). In addition, the studies were divided into univariate and multivariate analyses. The pooled hazard ratios were given as follows: univariate CSS = 1.75 [95% confidence interval (CI): 0.93-3.32; z= 1.69; P= .09]; multivariate CSS = 2.17 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate DFS = 2.11 (95% CI: 1.36-3.28; z= 3.32; P= .001); multivariate DFS = 2.15 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate OS and DFS = 2.30 (95% CI: 1.41-3.73; z= 3.36; P= .001); univariate OS = 2.28 (95% CI: 1.30-4.00; z= 2.89; P= .004). CONCLUSION: The results of the presented meta-analyses indicate that SMAD4 expression status using immunohistochemistry is a prognostic marker for patient survival. Neoplasia Press 2015-03-03 /pmc/articles/PMC4350636/ /pubmed/25749173 http://dx.doi.org/10.1016/j.tranon.2014.11.003 Text en © 2014 Neoplasia Press, Inc. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). |
spellingShingle | Article Voorneveld, Philip W. Jacobs, Rutger J. Kodach, Liudmila L. Hardwick, James C.H. A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() |
title | A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() |
title_full | A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() |
title_fullStr | A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() |
title_full_unstemmed | A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() |
title_short | A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer()() |
title_sort | meta-analysis of smad4 immunohistochemistry as a prognostic marker in colorectal cancer()() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350636/ https://www.ncbi.nlm.nih.gov/pubmed/25749173 http://dx.doi.org/10.1016/j.tranon.2014.11.003 |
work_keys_str_mv | AT voorneveldphilipw ametaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT jacobsrutgerj ametaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT kodachliudmilal ametaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT hardwickjamesch ametaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT voorneveldphilipw metaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT jacobsrutgerj metaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT kodachliudmilal metaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer AT hardwickjamesch metaanalysisofsmad4immunohistochemistryasaprognosticmarkerincolorectalcancer |